ERBB2 and breast cancer: A phosphoproteomic study defining breast cancer subtypes by non-negative matrix factorization (NMF) applied to genomic, transcriptomic, and proteomic data showed high levels of phosphorylated RAF1 and ARAF (considered surrogates of kinase activation) in Basal-I and HER2-I subtypes, respectively [73].